Rajarshi Banerjee, MD, PhD, MSc

In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.

In part 4 of our 5-part video series, Arab and Banerjee discuss how the study population of MAESTRO-NASH compares to MASH populations in real-world settings.

In part 3 of our 5-part discussion, Arab and Banerjee dive into the results of the pivotal MAESTRO-NASH trial and how it can inform use of resmetirom in real-world settings.

In part 2 of this 5-part video series, our experts in hepatology discuss the challenges, pitfalls, and recommendations for screening of MASH/MASLD in real-world settings.

In part 1 of this 5-part video series, our experts in hepatology discuss the recent change in nomenclature for NASH/NAFLD as compared to MASH/MASLD and how it effects management.